false
--12-31
0001860657
0001860657
2026-11-12
2026-11-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported)
November 12, 2026
ALLARITY THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
| Delaware |
|
001-41160 |
|
87-2147982 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
123 E Tarpon Ave,
Tarpon Springs, FL 34689
(Address of principal executive offices)
(401) 426-4664
(Registrant’s telephone number, including
area code)
Not applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| Common Stock, par value $0.0001 per share |
|
ALLR |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 1.01 Entry into a Material Definitive Agreement.
Exchange Agreement
On November 12, 2026, Allarity
Therapeutics, Inc. (the “Company”) entered into an Exchange Agreement (the “Exchange Agreement”) with Streeterville
Capital, LLC, a Utah limited liability company (“Streeterville”). The Exchange Agreement relates to the Company’s Promissory
Note A-1, dated March 2, 2026, in the original principal amount of $10,930,000 (the “A-1 Note”), issued pursuant to the Notes
Purchase Agreement, dated March 2, 2026, between the Company and Streeterville (the “Purchase Agreement”).
Pursuant to the Exchange
Agreement, the Company and Streeterville agreed to partition a new promissory note in the principal amount of $3,000,000 (the “Partitioned
Note”) from the A-1 Note and exchange the Partitioned Note for 3,000 shares (the “Exchange Shares”) of the Company’s
Series B Preferred Stock, par value $0.0001 per share (the “Series B Preferred Stock”). The Exchange Agreement provides that
the outstanding balance of the A-1 Note is reduced by $3,000,000. The partition became effective upon acceptance of the Certificate of
Designation described below by the Secretary of State of the State of Delaware. The Partitioned Note is evidenced by the Exchange Agreement,
without a separate note instrument.
On November 16, 2026, following
the filing and effectiveness of the Certificate of Designation, the Company completed the exchange and issued the Exchange Shares to Streeterville
in exchange for the surrender and cancellation of the Partitioned Note. The Company received no cash proceeds from the exchange, and Streeterville
provided no consideration other than the surrender of the Partitioned Note. Except as modified by the Exchange Agreement, the existing
transaction documents remain in effect.
Series B Preferred Stock
In connection with the exchange,
the Company’s Board of Directors approved a Certificate of Designation of Preferences and Rights of Series B Preferred Stock (the
“Certificate of Designation”) on November 12, 2026. The Certificate of Designation designated 5,000 shares of Series B Preferred
Stock, each with an initial stated value of $1,050 (the “Stated Value”). The 3,000 Exchange Shares have an aggregate initial
Stated Value of $3,150,000. The Certificate of Designation does not provide for conversion of the Series B Preferred Stock into shares
of the Company’s common stock, par value $0.0001 per share (the “Common Stock”).
Each share of Series B Preferred
Stock accrues a preferred return on its Stated Value at a rate of 9% per annum, compounded daily, from its issuance date (the “Preferred
Return”). The Preferred Return is payable quarterly, within five trading days following the end of each calendar quarter, in cash
or, at the Company’s election, in additional shares of Series B Preferred Stock. The number of additional shares is determined by
dividing the accrued and unpaid Preferred Return by $1,050, with cash paid in lieu of fractional shares.
The Series B Preferred Stock
ranks senior to the Common Stock and other junior capital stock with respect to dividends, distributions and payments upon liquidation,
dissolution or winding up. Upon a liquidation, dissolution or winding up, each share is entitled to its then-applicable Stated Value plus
accrued and unpaid Preferred Return, before any distribution to junior stockholders. After payment of that amount, the Series B Preferred
Stock does not participate in remaining liquidation distributions and does not participate in dividends or distributions to holders of
Common Stock. The Company may, at the discretion of its Board of Directors and subject to the Certificate of Designation, redeem all or
a portion of the outstanding Series B Preferred Stock for cash at the same amount (the “Redemption Price”). Notice is required
within ten trading days after the Board’s determination, and the redemption is to be completed on the third trading day after delivery
of the notice.
The Series B Preferred Stock
has no general voting rights and does not vote with the Common Stock. The Certificate of Designation requires the prior written consent
of holders of a majority of the outstanding Series B Preferred Stock (the “Required Holders”) to amend or repeal the Certificate
of Designation or to authorize or issue capital stock ranking senior to or pari passu with the Series B Preferred Stock as to the specified
preferences.
While any Series B Preferred
Stock remains outstanding, the Certificate of Designation imposes covenants that include maintaining the Company’s Exchange Act
reporting status and a listing or quotation of the Common Stock on Nasdaq, the New York Stock Exchange or NYSE American. Subject to the
terms and exceptions in the Certificate of Designation and the Side Letter described below, it also restricts additional issuances of
debt or equity securities, changes to authorized capital, pledges of assets, material asset dispositions outside the ordinary course of
business, certain reverse stock splits, and the entry into or consummation of a Fundamental Transaction, as defined in the Certificate
of Designation. That definition includes specified business combinations, reorganizations, transfers of material assets to affiliates
and distributions to stockholders outside the ordinary course of business. The reverse-stock-split restriction contains an exception for
a split in connection with satisfaction of a Nasdaq deficiency notice. Additional Series B Preferred Stock may be issued only to the initial
holder or its affiliates or assignees. The Company also may not enter into agreements restricting transactions with, or issuances of securities
to, holders of Series B Preferred Stock or their affiliates as specified in the Certificate of Designation.
The restrictions on additional
debt and equity issuances generally cover debt obligations other than trade payables incurred in the ordinary course of business, equity
securities, and securities convertible into or exchangeable for equity securities, with an exception for issuances or sales to a holder
of Series B Preferred Stock or its affiliates. The Side Letter provides a separate conditional consent for certain at-the-market sales,
as described below.
The Required Holders may
elect to declare an Event of Default upon specified covenant, payment or share-issuance defaults that remain uncured for five trading
days, or upon specified bankruptcy or insolvency events. Following an Event of Default, the Preferred Return increases to 15% per annum,
and the Required Holders may elect a one-time 15% increase in the Stated Value. Holders also may pursue available remedies, including
injunctive relief prohibiting issuances of Common Stock or preferred stock unless their Series B Preferred Stock is simultaneously redeemed
in full at the Redemption Price.
Side Letter
On November 12, 2026, the
Company and Streeterville also entered into a letter agreement regarding Conditional Consent to Future Use of ATM (the “Side Letter”).
Under the Side Letter, Streeterville consents to sales of Common Stock under any future at-the-market offering facility (an “ATM”),
notwithstanding the restriction on issuances in Section 10(e) of the Certificate of Designation. Streeterville may revoke the consent
at any time by written notice. For each week in which the Company sells Common Stock under its ATM, the Company must pay Streeterville
an amount equal to 33% of the net proceeds from all sales settled during that week (each, a “Sweep Payment”).
Streeterville may elect to
apply a Sweep Payment, in whole or in part, to redemption of its Series B Preferred Stock at the Redemption Price, repayment of the outstanding
balance of the A-1 Note, or both. In the absence of an election, a Sweep Payment is applied to redemption of Series B Preferred Stock
unless that redemption is not permitted by applicable law or the Certificate of Designation. Once the A-1 Note is paid in full or Streeterville
no longer holds Series B Preferred Stock, the entire Sweep Payment is applied to the other obligation. Upon request, the Company must
report the number of shares sold and gross proceeds from ATM sales during the preceding week. Failure to make a Sweep Payment when due
constitutes an event of default under the A-1 Note and the Certificate of Designation.
The Side Letter also provides
that, for purposes of note exchanges under Section 1.7 of the Purchase Agreement, the value of the Series B Preferred Stock held by Streeterville,
calculated as the number of shares multiplied by the Stated Value, is included in the aggregate outstanding balance of the A Notes. The
Side Letter controls in the event of a conflict with the Certificate of Designation and does not otherwise waive provisions of the parties’
other agreements or defaults under those agreements.
The foregoing descriptions
of the Certificate of Designation, Exchange Agreement and Side Letter do not purport to be complete and are qualified in their entirety
by reference to the full text of those documents, copies of which are filed as Exhibits 3.1, 10.1 and 10.2, respectively, to this Current
Report on Form 8-K and are incorporated herein by reference. The form of certificate representing the Series B Preferred Stock is filed
as Exhibit 4.1 to this Current Report on Form 8-K.
Item 3.02 Unregistered Sales of Equity Securities.
The information set forth
in Item 1.01 of this Current Report on Form 8-K regarding the exchange and issuance of the Exchange Shares is incorporated herein by reference.
The Exchange Shares were issued in reliance upon the exemption from registration provided by Section 3(a)(9) of the Securities Act of
1933, as amended. The Exchange Shares were exchanged exclusively with an existing security holder of the Company for securities of the
Company, and no commission or other remuneration was paid or given, directly or indirectly, for soliciting the exchange.
Item 3.03 Material Modification to Rights of Security Holders.
The information set forth
in Items 1.01 and 5.03 of this Current Report on Form 8-K is incorporated herein by reference. Upon issuance of the Exchange Shares on
the closing date described in Item 1.01, the rights of holders of Common Stock became subject to the senior preferences, protective provisions
and covenants applicable to the Series B Preferred Stock, including its priority with respect to dividends, distributions and payments
upon liquidation, dissolution or winding up, and the restrictions on specified issuances, capital changes and transactions described above.
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change
in Fiscal Year.
On November 12, 2026, the
Company filed the Certificate of Designation with the Secretary of State of the State of Delaware, which became effective on November
12, 2026. The Certificate of Designation establishes the rights, preferences and limitations of a new series of 5,000 shares of Series
B Preferred Stock from the Company’s authorized preferred stock. The information set forth in Item 1.01 of this Current Report on
Form 8-K regarding the Certificate of Designation is incorporated herein by reference. A copy of the Certificate of Designation is filed
as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 8.01 Other Events.
On November 16, 2026, the
Company issued a press release announcing an expansion of eligibility for its ongoing Phase 2 trial of stenoparib, a dual PARP and WNT
pathway inhibitor, in advanced ovarian cancer to include patients with primary platinum-refractory disease and patients whose disease
is clinically evaluable but not measurable under standard Response Evaluation Criteria in Solid Tumors. A copy of the press release is
filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
Number |
|
Description |
| 3.1 |
|
Certificate of Designation of Preferences and Rights of Series B Preferred Stock of Allarity Therapeutics, Inc. |
| 4.1 |
|
Form of Series B Preferred Stock Certificate. |
| 10.1 |
|
Exchange Agreement, dated November 12, 2026, by and between Allarity Therapeutics, Inc. and Streeterville Capital, LLC. |
| 10.2 |
|
Letter Agreement, dated November 12, 2026, by and between Allarity Therapeutics, Inc. and Streeterville Capital, LLC. |
| 99.1 |
|
Press Release, dated November 16, 2026. |
| 104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
Allarity Therapeutics, Inc. |
| |
|
|
| Date: November 17, 2026 |
By: |
/s/ Thomas H. Jensen |
| |
|
Thomas H. Jensen
Chief Executive Officer |
Exhibit 99.1

Allarity Therapeutics Expands Phase
2 Stenoparib Trial to Three Ovarian Cancer Patient Cohorts
Investigator-supported move capitalizes
on strong enrollment momentum and encouraging early clinical observations
Adds platinum-refractory patients
as well as those with hard-to-measure but clinically evaluable disease
Leverages existing clinical sites to evaluate
groups independently and accelerate potential paths to commercialization
TARPON SPRINGS, Fla., November 16, 2026 – Allarity Therapeutics,
Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to
developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor— today confirmed expanded eligibility
for its ongoing Phase 2 trial in advanced ovarian cancer. This opens the study to patients with primary platinum-refractory disease and
patients whose disease can be evaluated clinically but is not measurable under standard Response Evaluation Criteria in Solid Tumors (“RECIST”).
The expansion into additional patient populations was prompted by the
enthusiasm of clinical investigators for the potential of stenoparib as a well-tolerated, oral treatment option for advanced ovarian cancer
patients and reflects the encouraging early performance of the ongoing trial in platinum-resistant and platinum-ineligible patients. Importantly,
the addition of these new patients now allows Allarity to build upon prior evidence of remarkable, durable clinical benefit in primary
platinum-refractory disease while also evaluating stenoparib’s potential role across a broader spectrum of advanced ovarian cancer patients.
“We are excited about the expansion of eligibility to include
patients with primary platinum-refractory disease as well as those with resistant but not measurable disease, allowing access to a potentially
effective therapeutic agent among patients routinely excluded from clinical trial participation. We are hopeful that these patients
will benefit from stenoparib and that we can learn more about best treatment options for all patients with ovarian cancer,” said
Kathleen N. Moore, M.D., M.S., Principal Investigator of the Phase 2 stenoparib trial, Deputy Director and Director of Phase I Oncology
Trials at the Fred & Pamela Buffett Cancer Center, and Professor in the Department of Obstetrics and Gynecology at the University
of Nebraska Medical Center.
“We’re encouraged by the progress we’ve seen in the trial,
and we’re excited to build on it,” said Thomas Jensen, Chief Executive Officer of Allarity Therapeutics. “The strategic
expansion of patient eligibility in this trial allows us to efficiently map the potential of stenoparib across multiple high-unmet-need
populations. A strong result in any one of the three groups could support further development. And if the data support development in
more than one group, stenoparib could ultimately reach more patients and address a larger market.”
Allarity Therapeutics,
Inc. | 123 E Tarpon Ave | Tarpon Springs, Florida | U.S.A. | NASDAQ: ALLR | www.allarity.com

Earlier Findings Justify Broader Evaluation
The ongoing Phase 2 study builds on findings
from earlier experience in the trial. In heavily pretreated patients with advanced, recurrent ovarian cancer, previously presented
observations at the ESMO Gynaecological Cancers Congress in June 2026 included:
| ● | Treatment
Duration and Survival: In a patient with primary platinum-refractory disease, treatment duration was nearly 1 year with survival
exceeding 2 years. |
| ● | Clinical
Benefit: Extended clinical benefit in platinum-resistant ovarian cancer patients with BRCA-mutant and BRCA-wild-type disease, with
some patients staying on drug nearly 2.5 years. |
| ● | Complete,
Confirmed Response: An unprecedented response in a heavily pretreated platinum-resistant patient retreated with a PARP inhibitor. |
| ● | Median
Overall Survival: A median Overall Survival (mOS) of 22 months in patients treated with stenoparib (this compares favorably to recent
U.S. Food and Drug Administration (FDA) approved drugs showing mOS in similar patients of ~16 months). |
Consistent with its long-standing clinical data reporting policy, Allarity
will release clinical and scientific data at future scientific and clinical conferences.
About Allarity Therapeutics
Allarity Therapeutics, Inc. (NASDAQ: ALLR) is
a clinical-stage pharmaceutical company focused on developing personalized cancer treatments. The Company is developing stenoparib, a
novel PARP/tankyrase inhibitor for patients with advanced ovarian cancer, and is using its proprietary DRP® technology
to develop a companion diagnostic designed to identify patients expected to derive the greatest clinical benefit from stenoparib. Allarity’s
principal operations are located in Denmark, and its U.S. business address is in Florida. For more information, visit www.allarity.com.
About Stenoparib/2X-121
Stenoparib is an orally available, small-molecule dual-targeted inhibitor
of PARP1/2 and tankyrase 1/2. Tankyrases have emerged as potential therapeutic targets in cancer due in part to their role in regulating
the WNT signaling pathway. Aberrant WNT/β-catenin signaling has been implicated in the development and progression of numerous cancers,
including drug-resistant cancers. Through its inhibition of PARP and the WNT signaling pathway, stenoparib has the potential to provide
therapeutic benefit across multiple cancer types, including ovarian cancer, small cell lung cancer and colorectal cancer.
Allarity has secured exclusive global rights to develop and commercialize
stenoparib, which was originally developed by Eisai Co., Ltd. and was formerly known as E7449 and 2X-121.
Under an earlier Phase 2 protocol evaluating stenoparib in patients
with advanced ovarian cancer, Allarity observed promising and durable clinical benefit in patients with ovarian cancer who received two
or more prior lines of therapy and were treated with stenoparib twice daily. Updated data from this earlier protocol were presented at
the AACR Special Conference on Advances in Ovarian Cancer in September 2025. These analyses remain subject to change as the study data
mature.
Allarity Therapeutics,
Inc. | 123 E Tarpon Ave | Tarpon Springs, Florida | U.S.A. | NASDAQ: ALLR | www.allarity.com

Based on the emerging clinical experience with stenoparib, Allarity
developed a new protocol focused on patients with platinum-resistant ovarian cancer, which began enrolling patients in the summer of 2025.
The previous protocol enrolls platinum-resistant or platinum-ineligible patients. Allarity has amended the protocol to add two patient
groups that will be evaluated separately from the original cohort, namely patients with primary platinum-refractory disease and patients
whose disease can be evaluated clinically but is not measurable under standard Response Evaluation Criteria in Solid Tumors (“RECIST”).
The study is designed to advance the clinical development of stenoparib toward potential FDA approval.
In parallel, a separate Phase 2 trial evaluating stenoparib in combination
with temozolomide for patients with relapsed small cell lung cancer, or SCLC, began enrolling in early 2026 and is currently enrolling
patients at multiple U.S. Department of Veterans Affairs sites.
About the Drug Response Predictor – DRP® Companion
Diagnostic
Allarity uses its drug-specific DRP®
technology to identify patients who, based on the gene expression signature of their cancer, may be more likely to benefit from a particular
drug. By screening patients before treatment, and selecting those with a sufficiently high, drug-specific DRP score, the DRP technology
is designed to increase the likelihood of therapeutic benefit.
The DRP methodology is based on the comparisons of sensitive and resistant
human cancer cell lines, and incorporates transcriptomic data, clinical tumor biology filters and prior clinical trial outcomes. The DRP
uses messenger RNA expression profiles derived from patient biopsies to generate drug-specific predictive scores.
The DRP® platform has demonstrated
the ability to provide statistically significant predictions of clinical outcome following drug treatment across dozens of retrospective
and prospective clinical studies. The platform is designed for potential application across multiple cancer types, is patented for dozens
of anti-cancer drugs and has been extensively described in peer-reviewed scientific literature.
Follow Allarity on Social Media
LinkedIn: https://www.linkedin.com/company/allaritytx/
Allarity Therapeutics,
Inc. | 123 E Tarpon Ave | Tarpon Springs, Florida | U.S.A. | NASDAQ: ALLR | www.allarity.com

Forward-Looking Statements
This press release contains forward-looking statements
within the meaning of applicable federal securities laws. Forward-looking statements reflect current expectations or forecasts regarding
future events. The words “anticipates,” “believes,” “continues,” “could,” “estimates,”
“expects,” “intends,” “may,” “might,” “plans,” “possible,” “potential,”
“predicts,” “projects,” “should,” “would” and similar expressions may identify forward-looking
statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include,
but are not limited to, statements regarding continued enrollment and conduct of the Company’s ongoing Phase 2 trial of stenoparib
in advanced ovarian cancer; the enrollment, treatment and evaluation of additional patient populations under the amended protocol; the
interpretation and further evaluation of clinical observations and their potential relationship to findings from the earlier Phase 2
protocol; the potential clinical benefit of stenoparib, including treatment duration and survival outcomes; the potential for the additional
patient populations to provide further clinical, regulatory or commercial development opportunities for stenoparib, including the potential
to reach additional patients and address a larger market; the continued development and potential regulatory approval of stenoparib and
its DRP® companion diagnostic; and the Company’s plans for future scientific presentations and clinical data disclosures,
including the timing and scope of such disclosures. Any forward-looking statements in this press release are based on management’s
current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially
from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to,
risks related to delays or difficulties in patient enrollment, treatment, follow-up, data collection or analysis; the possibility that
implementing the amendment may take longer or cost more than anticipated, or that using the existing trial infrastructure may not yield
the expected efficiencies; the possibility that preliminary observations may change as additional data become available or following
further review; the risk that current or future studies may not confirm findings from the earlier protocol or demonstrate sufficient
safety or clinical benefit; the possibility that clinical outcomes in the additional patient populations may differ from prior observations
or may not support broader clinical development, regulatory approval or commercial opportunities; differences in patient populations
and study protocols that may limit comparisons; uncertainty regarding treatment duration and overall survival; the possibility that stenoparib
or its DRP® companion diagnostic may not receive regulatory approval; changes or delays in scientific presentation or
data disclosure plans, including those arising from data availability, conference acceptance or applicable embargo requirements; and
the Company’s ability to secure sufficient financing and other resources to continue development. For a discussion of risks and
uncertainties and other important factors that could cause actual results to differ materially from those contained in the forward-looking
statements, see the risk factors and other disclosures in Allarity’s filings with the SEC, including its most recent Annual Report
on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. These filings are available through the SEC’s
website. All information in this press release is as of the date of the release, and the Company undertakes no obligation to update or
revise this information, except as required by applicable law.
###
Company Contact:
investorrelations@allarity.com
Allarity Therapeutics,
Inc. | 123 E Tarpon Ave | Tarpon Springs, Florida | U.S.A. | NASDAQ: ALLR | www.allarity.com